Her2 Positive Breast Cancer

Her2 Positive Breast Cancer Book PDF
✏Book Title : HER2 Positive Breast Cancer
✏Author : Sara Hurvitz
✏Publisher : Elsevier Health Sciences
✏Release Date : 2018-07-26
✏Pages : 264
✏ISBN : 9780323581233
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏HER2 Positive Breast Cancer Book Summary : Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Mechanisms Of Resistance To T Dm1 In Her2 Positive Breast Cancer Book PDF
✏Book Title : Mechanisms of Resistance to T DM1 in HER2 positive Breast Cancer
✏Author : Junjie Zhang
✏Publisher :
✏Release Date : 2018
✏Pages : 122
✏ISBN : 8449080320
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Mechanisms of Resistance to T DM1 in HER2 positive Breast Cancer Book Summary : El cĂĄncer de mama HER2-positivo representa alrededor del 15-30% del total de pacientes con cĂĄncer de mama. Este subtipo tiene un mal pronĂłstico, seguido del subtipo Triple-negativo (TNBC), que lo tiene aĂșn peor. Actualmente, varios medicamentos estĂĄn aprobados para las pacientes HER2-positivo, como Trastuzumab, Lapatinib y T-DM1. Sin embargo, a menudo Ă©stas adquieren resistencia a estas terapias en un perĂ­odo de 1 a 2 años. El objetivo principal de este estudio es definir los mecanismos de resistencia a T-DM1. Durante mi tesis, generĂ© lĂ­neas celulares resistentes a T-DM1 y explorĂ© diferentes posibilidades in vitro que pudieran explicar cĂłmo estas cĂ©lulas escapan de la terapia contra HER2. Obtuve cĂ©lulas resistentes a T-DM1 usando una lĂ­nea celular derivada de un tumor primario de una paciente (PDX, Patient-derived xenograft) tratĂĄndolas con dosis crecientes de T-DM1. ComprobĂ© los niveles de HER2 por mRNA y proteĂ­na, nĂșmero de copias, efectores de señalizaciĂłn, analicĂ© la regiĂłn citotĂłxica de T-DM1 y su actividad lisosĂłmica diferencial comparando la lĂ­nea parental y las cĂ©lulas resistentes. Esta tesis describe punto por punto todos los posibles mecanismos de resistencia que investigamos y cuales resultaron ser los responsables de la resistencia a T-DM1.

Erbb2 Her2 Positive Breast Cancer Book PDF
✏Book Title : ErbB2 HER2 positive Breast Cancer
✏Author : KARGER
✏Publisher :
✏Release Date : 2010
✏Pages : 28
✏ISBN : 3805595093
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏ErbB2 HER2 positive Breast Cancer Book Summary :

Gut Microbiota And Trastuzumab Response In Her2 Positive Breast Cancer Book PDF
✏Book Title : Gut Microbiota and Trastuzumab Response in HER2 positive Breast Cancer
✏Author : Martina Di Modica
✏Publisher :
✏Release Date : 2020
✏Pages :
✏ISBN : OCLC:1197765341
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Gut Microbiota and Trastuzumab Response in HER2 positive Breast Cancer Book Summary :

Resistance To Her2 Targeted Therapies In Her2 Positive Breast Cancer Book PDF
✏Book Title : Resistance to HER2 targeted Therapies in HER2 positive Breast Cancer
✏Author : Natasha Tracey
✏Publisher :
✏Release Date : 2019
✏Pages :
✏ISBN : OCLC:1122176732
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Resistance to HER2 targeted Therapies in HER2 positive Breast Cancer Book Summary :

Immunotherapy Against Her2 Positive Breast Cancers Book PDF
✏Book Title : Immunotherapy Against HER2 positive Breast Cancers
✏Author : Rocío Vicario
✏Publisher :
✏Release Date : 2016
✏Pages : 119
✏ISBN : 8449068762
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Immunotherapy Against HER2 positive Breast Cancers Book Summary : El 20% de los tumores mamarios sobre expresan el receptor de tirosina quinasa HER2, debido a su amplificaciĂłn gĂ©nica, tanto dentro de los cromosomas (HSR) como fuera ellos (DM). Se sabe muy poco acerca de la respuesta clĂ­nica o el rol en resistencia a terapias de estos patrones de amplificaciĂłn. Por otro lado, un porcentaje de pacientes HER2+ expresa fragmentos carboxyl-terminales de HER2, p95HER2. Mas de la mitad de pacientes HER2+ no responde a las terapias disponibles. Hasta el momento, se desconoce si p95HER2 puede ser un blanco terapĂ©utico. En este trabajo estudiaremos resistencias a terapias anti-HER2 y desarrollaremos nuevas terapias para el tratamiento de tumores p95HER2/HER2+. En esta tesis, evaluamos si el patrĂłn de amplificaciĂłn tiene impacto en la respuesta terapĂ©utica. Mostramos que el ̃30% de los tumores HER2+ tienen amplificaciĂłn en DM pero responden a la terapia de la misma manera que los HSR. El nĂșmero de DM se mantiene cuando se desarrolla resistencia a la terapia, incluso si se pierde expresiĂłn proteica de HER2. Por lo tanto, la perdida de DM no parece ser un mecanismo de resistencia a terapias anti-HER2. Por otro lado, tambiĂ©n evaluamos si p95HER2 puede ser un blanco para inmunoterapia. Presentamos un anticuerpo bi-especifico de cĂ©lulas T (p95-TCB) que se une a p95HER2 en la cĂ©lula tumoral y a CD3e, miembro del receptor de cĂ©lulas T, presente en linfocitos T. La uniĂłn simultanea a la cĂ©lula tumoral y a la cĂ©lula T induce la activaciĂłn de la cĂ©lula T, la secreciĂłn de grĂĄnulos citotĂłxicos y la lisis de la cĂ©lula tumoral. En modelos pre-clĂ­nicos, mostramos que p95-TCB aumenta la infiltraciĂłn de cĂ©lulas T y promueve la regresiĂłn tumoral. Comparado con HER2-TCB, p95-TCB tiene la ventaja de discriminar las cĂ©lulas normales con baja expresiĂłn de HER2 previniendo efectos colaterales. En resumen, este trabajo descarta a los DMs como predictores de respuesta a terapias anti-HER2, y describe un nuevo anticuerpo bi-especifico que recluta y active cĂ©lulas inmunes a los tumores p95HER2/HER2+ y como consecuencia la regresiĂłn de los mismos.

Dna Methylome In Her2 Positive Resistant Breast Cancer Book PDF
✏Book Title : DNA Methylome in HER2 positive Resistant Breast Cancer
✏Author : SĂČnia Palomeras
✏Publisher :
✏Release Date : 2019
✏Pages : 226
✏ISBN : OCLC:1151062533
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏DNA Methylome in HER2 positive Resistant Breast Cancer Book Summary : The major clinical problem for HER2+ breast cancer target therapies is the acquisition of resistance. The DNA methylation status of the promoter gene region has been described as a common epigenetic alteration for transcriptional repression in human malignancies as breast cancer. The purpose of this thesis was to evaluate how the DNA methylation was involved in trastuzumab and lapatinib resistance in HER2+ breast cancer. We identify the epigenetic silencing of the TGFBI gene in trastuzumab resistance HER2+ breast cancer cell model and in post-treatment samples of patients treated with neoadjuvant anthracycline-taxane-based chemotherapy plus trastuzumab. Furthermore, the in vitro analysis revealed that the TGFBI reexpression induced greater sensitivity to trastuzumab in our resistant model, probably through its integrin-binding domains (EPDIM, NKDIL, YH and RGD). These results provide a basis for further studies to validate the hypermethylation status of TGFBI gene as monitoring biomarkers of trastuzumab resistance in HER2 breast cancer patients.

Exploring Prognostic Factors For Her2 Positive Metastatic Breast Cancer Book PDF
✏Book Title : Exploring Prognostic Factors for HER2 positive Metastatic Breast Cancer
✏Author : Lilian Germaine Bringolf
✏Publisher :
✏Release Date : 2017
✏Pages :
✏ISBN : OCLC:995263655
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Exploring Prognostic Factors for HER2 positive Metastatic Breast Cancer Book Summary :

The Human Epidermal Growth Factor Receptor 2 Her2 In The Breast Cancer Book PDF
✏Book Title : The Human Epidermal Growth Factor Receptor 2 HER2 in the Breast Cancer
✏Author : Daniela Furrer
✏Publisher :
✏Release Date : 2017
✏Pages : 307
✏ISBN : OCLC:1153660164
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏The Human Epidermal Growth Factor Receptor 2 HER2 in the Breast Cancer Book Summary : The overexpression of the human epidermal growth factor receptor 2 (HER2) and/or HER2 gene amplification are predictive factors in breast cancer. Following the HER2-targeted treatment with trastuzumab, the reliable evaluation of HER2 has become essential. Unfortunately, up to 50% of HER2-positive breast cancer patients develop resistance towards this drug. The objectives were: 1). To determine the most reliable and economical method to evaluate HER2 status (cohort of 521 consecutive breast cancer cases); 2). To examine the association between tobacco and alcohol consumption, and two HER2 polymorphisms (Ile655Val and Ala1170Pro), and the response to trastuzumab (cohort of 236 HER2-positive breast cancer patients treated with trastuzumab). Moreover, in a pilot study, we explored the association between genome-wide DNA methylation patterns in breast cancer tissues and the response to trastuzumab (cohort of 12 breast cancer patients treated with trastuzumab). HER2 status was evaluated by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and TaqMan assay. We compared HER2 status determined by FISH on whole tissue (WT, one tissue per slide) section and tissue microarray (TMA, 60 tissues per slide) section, and HER2 status evaluated by IHC and FISH on the block used for diagnostic (diagnostic block) and on a randomly chosen additional block (random block). Clinicopathological information were assessed by review of medical records, tobacco and alcohol consumption by an administered validated questionnaire. DNA methylation patterns were evaluated using the Illumina Infinium HumanMethylation450 BeadChip. Overall concordance between HER2 status determined by FISH on WT and TMA sections was 98.2% and that between diagnostic and random blocks was 98.0% for FISH and 93.6% for IHC. Tobacco consumption and the Val allele were associated with a worse response, whereas alcohol consumption was associated with a better response. Methylation pattern in tumor tissues of HER2-positive breast cancer patients who acquired resistance to trastuzumab treatment differed from that of HER2-positive breast cancer patients who responded to trastuzumab treatment. However, this observation seemed to depend upon the method of bioinformatics analysis used. We conclude that FISH performed on TMA section represents a reliable and economical method for the evaluation of HER2. Results obtained by FISH, but not those obtained by IHC, fulfill the recommendations of the College of American Pathologists of concordance greater than 95% between the reference method and the new method. Tobacco use, alcohol consumption and Ile655Val HER2 polymorphism might influence the response to trastuzumab treatment.

Decreased Expression Of Stomatin Predicts Poor Prognosis In Her2 Positive Breast Cancer Book PDF
✏Book Title : Decreased Expression of Stomatin Predicts Poor Prognosis in HER2 Positive Breast Cancer
✏Author : Atibaia Atibaia Press
✏Publisher :
✏Release Date : 2016-11-22
✏Pages : 36
✏ISBN : 1540582361
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Decreased Expression of Stomatin Predicts Poor Prognosis in HER2 Positive Breast Cancer Book Summary : Human epidermal growth factor receptor-2 (HER2) is a transmembrane tyrosine kinase receptor that is overexpressed in 25 to 30 % of human breast cancers and is preferentially localized in lipid rafts. Stomatin is a membrane protein that is absent from the erythrocyte plasma membrane in patients with congenital stomatocytosis and is the major component of the lipid raft. Proceeds from the sale of this book go to support an elderly disabled person.

📒Adjuvant Therapy For Breast Cancer ✍ Monica Castiglione

Adjuvant Therapy For Breast Cancer Book PDF
✏Book Title : Adjuvant Therapy for Breast Cancer
✏Author : Monica Castiglione
✏Publisher : Springer Science & Business Media
✏Release Date : 2009-07-11
✏Pages : 490
✏ISBN : 0387751157
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Adjuvant Therapy for Breast Cancer Book Summary : Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.

The Electronics Of Her2 Neu Positive Breast Cancer Cells Book PDF
✏Book Title : The Electronics of HER2 neu Positive Breast Cancer Cells
✏Author : Jan Baumann
✏Publisher :
✏Release Date : 2011
✏Pages :
✏ISBN : OCLC:1154180806
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏The Electronics of HER2 neu Positive Breast Cancer Cells Book Summary : The Electronics of HER2/neu Positive Breast Cancer Cells.

Handbook Of Her2 Targeted Agents In Breast Cancer Book PDF
✏Book Title : Handbook of HER2 targeted agents in breast cancer
✏Author : Ricardo H Alvarez
✏Publisher : Springer
✏Release Date : 2014-05-28
✏Pages : 96
✏ISBN : 9781907673948
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Handbook of HER2 targeted agents in breast cancer Book Summary : ​Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.

Cardiac Toxicity Of Her2 Directed Therapy In Women With Breast Cancer Epidemiology Etiology Risk Factors And Management Book PDF
✏Book Title : Cardiac Toxicity of HER2 Directed Therapy in Women with Breast Cancer Epidemiology Etiology Risk Factors and Management
✏Author : Shahid Ahmed
✏Publisher :
✏Release Date : 2017
✏Pages :
✏ISBN : OCLC:1154237257
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Cardiac Toxicity of HER2 Directed Therapy in Women with Breast Cancer Epidemiology Etiology Risk Factors and Management Book Summary : The HER2-targeted therapy have profoundly changed the outcomes of women with HER2-positive breast cancers. Trastuzumab and pertuzumab, HER2-targeting monoclonal antibodies, lapatinib and Neratinib, small molecule inhibitors of HER2 and the epidermal growth factor receptor, and ado-trastuzumab emtansine, a HER2-positive directed antibody drug conjugate, are approved for the treatment of HER2-positive breast cancer.

Role Of 16her2 Splice Variant In The Aggressiveness And Response Of Her2 Positive Breast Cancer To Drugs Targeting Her2 Receptor Book PDF
✏Book Title : Role of 16HER2 Splice Variant in the Aggressiveness and Response of HER2 positive Breast Cancer to Drugs Targeting HER2 Receptor
✏Author : Gaia Cristina Ghedini
✏Publisher :
✏Release Date : 2015
✏Pages : 193
✏ISBN : OCLC:1109058108
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Role of 16HER2 Splice Variant in the Aggressiveness and Response of HER2 positive Breast Cancer to Drugs Targeting HER2 Receptor Book Summary :

Analysis Of Organotropic Metastasis In Relation To Herceptin Response Of Her2 Positive Breast Cancer Cells Book PDF
✏Book Title : Analysis of Organotropic Metastasis in Relation to Herceptin Response of HER2 Positive Breast Cancer Cells
✏Author : Justin Molnar
✏Publisher :
✏Release Date : 2017
✏Pages : 55
✏ISBN : OCLC:1192965916
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Analysis of Organotropic Metastasis in Relation to Herceptin Response of HER2 Positive Breast Cancer Cells Book Summary : HER2 (Epidermal Growth Factor Receptor Type 2) positive breast cancer accounts for 20-30 percent of cases and is associated with increased tumor cell proliferation, resistance to hormonal therapies and decreased patient survival. Trastuzumab (Herceptin¼, Genentech-Roche) induces cytotoxicity in HER2+ breast cancer, significantly increases patient survival and is one of only a few targeted therapies approved for this aggressive malignancy. However, the majority of patients that qualify for this line of therapy exhibit innate or acquired resistance and must stop treatment. Herceptin resistance is associated with increased incidence of local invasion and systemic metastasis, and there is a need for in vivo methods to study the metastatic potential of Herceptin resistant and sensitive HER2+ breast cancer cells. Here, we have used the chicken (Gallus gallus) embryo chorioallantoic membrane (CAM) to establish an in vivo model of spontaneous metastasis for evaluating organotropism in Herceptin sensitive (SKBR3 and BT474) and resistant (AU565/innate and BT474-HR6/acquired) HER2+ breast cancer cells. Importantly, we demonstrate for the first time that Herceptin resistant cells are significantly more metastatic than their sensitive counterparts. We confirmed these results in vitro using 4D confocal microscopy and demonstrate that Herceptin resistant cells are also more invasive. Most notably, we report significant differences in the organotropisms for HER2+ breast cancer cells with innate versus acquired Herceptin resistance. Innately resistant cells exhibit significant increases in pulmotropic and hepatotropic metastases consistent with their increased expression of KRT81 and ID1. Alternatively, cells with acquired resistance exhibit significant increases in neurotropic metastasis consistent with their increased expression of HBEGF. Interestingly, cancer-associated fibroblasts (CAFs) derived from HER2+ breast cancer patients have been previously reported to also express elevated levels of HBEGF, suggesting that HER2+ CAFs may potentiate Herceptin resistance and neurotropic metastasis. To evaluate the role of stromal fibroblasts on HER2+ breast cancer cell organotropism, we first co-xenografted embryonic fibroblasts together with HER2+ breast cancer cells into the CAM model - we observed selective prometastatic effects of these stromal fibroblasts only on Herceptin resistant cells. We propose that this novel co-xenografting in vivo model can be used to evaluate the regulatory effects of patient-derived CAFs on organotropism of HER2+ breast cancer cells in relation to their Herceptin responsiveness. Findings from these studies will illuminate the cellular and molecular mechanisms that drive organotropism in aggressive and therapy-refractory breast cancers.

Drugs For Her 2 Positive Breast Cancer Book PDF
✏Book Title : Drugs for HER 2 positive Breast Cancer
✏Author : Maria Sibilia
✏Publisher : Springer Science & Business Media
✏Release Date : 2011-01-06
✏Pages : 110
✏ISBN : 3034600941
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Drugs for HER 2 positive Breast Cancer Book Summary : Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

Breast Cancer Ect V1 I 3 Book PDF
✏Book Title : Breast Cancer ECT V1 I 3
✏Author :
✏Publisher : Demos Medical Publishing
✏Release Date : 2010-12-16
✏Pages : 240
✏ISBN : 9781617050435
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Breast Cancer ECT V1 I 3 Book Summary : Breast Cancer: Breast cancer is second only to lung cancer as the leading cancer cause of death in women. In 2010 207,000 women will be diagnosed with breast cancer and over 39,000 are expected to die from breast cancer. Nevertheless, ongoing research and recent advances in both diagnostic and therapeutic modalities continue to make breast cancer management a rapidly evolving area in which the practitioner will want to be fully updated on current developments. Breast Cancer offers a comprehensive and in-depth review of the current literature of breast cancer. Chapters examine risk factors and prevention strategies, trends and developments in imaging, surgical management, radiotherapy advances, adjuvant endocrine and chemotherapies, targeted metastatic therapy, and the role of bisphosphonates and novel bone agents in breast cancer. With this volume the oncology practitioner will have a full and current overview of all significant current trends in this important area of oncology. About the Series: Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging. Features of Emerging Cancer Therapeutics include: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice

Quantifying Tumor Evolutionary Dynamics And Predictors Of Response In Her2 Positive Breast Cancer Treated With Targeted Therapy Book PDF
✏Book Title : Quantifying Tumor Evolutionary Dynamics and Predictors of Response in HER2 positive Breast Cancer Treated with Targeted Therapy
✏Author : Katherine Lee McNamara
✏Publisher :
✏Release Date : 2020
✏Pages :
✏ISBN : OCLC:1164100571
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Quantifying Tumor Evolutionary Dynamics and Predictors of Response in HER2 positive Breast Cancer Treated with Targeted Therapy Book Summary : Evolution during treatment is a significant clinical problem that leads to treatment failure, resistance, and disease progression in many solid tumors, including breast cancer. Through analysis of clinical tissue samples and using a combination of established genomic techniques, computational modeling, and novel molecular profiling methods, this dissertation explores how HER2-positive breast tumors evolve under systemic therapy and characterizes predictors of treatment response. First using multi-region genomic sequencing and computational modeling, we show that the mutational landscape of a tumor can shift dramatically over a few months of combination chemotherapy and HER2-targeted therapy (termed "clonal replacement"). We then utilized tissue from a neoadjuvant HER2-positive breast cancer clinical trial to explore tumor-associated and immune-associated predictors of treatment response. We demonstrate the utility of spatial proteomic analysis of on-treatment biopsies to define biomarkers that stratify sensitive tumors early during neoadjuvant HER2-targeted therapy with implications for tailoring subsequent therapy. Taken together, our results shed light on the roles of heterogeneity, the frequency of resistance-causing aberrations, and the immune microenvironment in response to HER2-targeted therapy. In addition, our results also provide insights into the design of clinical trials that have a molecular analysis component.

Her2 Positive Breast Cancer Is More Treatment Better  Book PDF
✏Book Title : HER2 positive Breast Cancer is More Treatment Better
✏Author :
✏Publisher :
✏Release Date : 2016
✏Pages :
✏ISBN : OCLC:1052046549
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏HER2 positive Breast Cancer is More Treatment Better Book Summary :

Disparities Of Trastuzumab Use In Resource Limited Or Resource Abundant Regions And Its Survival Benefit On Her2 Positive Breast Cancer A Real World Study From China Book PDF
✏Book Title : Disparities of Trastuzumab Use in Resource Limited Or Resource Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer A Real World Study from China
✏Author :
✏Publisher :
✏Release Date : 2017
✏Pages :
✏ISBN : OCLC:1053696585
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Disparities of Trastuzumab Use in Resource Limited Or Resource Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer A Real World Study from China Book Summary : Abstract: Background: Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real‐world data are lacking, the present research was conducted to evaluate the actual use of and the effectiveness of trastuzumab in the real world in China. Methods: Inpatients with HER2 positive invasive breast cancer from 13 hospitals in Eastern China (2010–2015, n = 1, 139) were included in this study. We aimed to assess the actual use of trastuzumab and to evaluate potential efficacy from trastuzumab in real‐world research. Results: Of 1, 017 patients with early stage breast cancer (EBC), 40.5% (412/1, 017) received trastuzumab therapy. Patients with EBC in resource‐abundant regions (gross domestic product per capita >$15, 000 and trastuzumab included in Medicare) are more likely to receive trastuzumab than those in resource‐limited regions (37.3% vs. 13.0%, p

Systemic Treatment Of Her2 Positive Metastatic Breast Cancer A Systematic Review Book PDF
✏Book Title : Systemic Treatment of HER2 positive Metastatic Breast Cancer A Systematic Review
✏Author :
✏Publisher :
✏Release Date : 2014
✏Pages :
✏ISBN : OCLC:1051406099
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Systemic Treatment of HER2 positive Metastatic Breast Cancer A Systematic Review Book Summary : Abstract: Aim: We aimed to systematically review and summarize data from the available clinical trials that examined the treatment of HER2‐positive metastatic breast cancer. Methods: We reviewed phase 2 and 3 studies in which an anti‐HER2 agent was used in one or both arms of the study. While formal meta‐analysis was not possible for such a heterogeneous group of trials, resulting forest plots outline some generalizable findings. Results: There is strong evidence that the addition of an anti‐HER2 agent to standard chemo‐ or endocrine therapy improves clinically relevant measurable outcomes. There is also consistent evidence that initial treatment with trastuzumab alone (and subsequent use of a cytotoxic) is inferior to the initial combination of trastuzumab plus chemotherapy, and that either T‐DM1 or dual anti‐HER2 agents are superior to single anti‐HER2 agent regimens. There is no strong evidence that the use of more than one cytotoxic agent together with an anti‐HER2 agent confers any benefit over a single cytotoxic, anti‐HER2 combination. Conclusion: This review provides a strong evidence base for current clinical practice with a discussion of treatment in the Australian setting.

Uncivering Mechanisms Of Acquired Resistance To Trastuzumab Emtansine T Dm1 In Her2 Positive Breast Cancer Book PDF
✏Book Title : Uncivering Mechanisms of Acquired Resistance to Trastuzumab emtansine T DM1 in HER2 Positive Breast Cancer
✏Author : Mohammad Ali Sabbaghi Mehrjardi
✏Publisher :
✏Release Date : 2017
✏Pages : 177
✏ISBN : OCLC:1022581097
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Uncivering Mechanisms of Acquired Resistance to Trastuzumab emtansine T DM1 in HER2 Positive Breast Cancer Book Summary : "Trastuzumab-emtansine (T-DM1) is an antibody-cytotoxic agent (DM1) conjugated drug. DM1 delivery by trastuzumab inside the HER2 positive cells affects microtubule polymerization, cell cycle arrest and finally cell death. Although T-DM1 is approved for the treatment of HER2 positive metastatic breast cancer patients, primary and acquired resistance towards this drug is still a main challenge. Looking for the mechanisms of resistance is necessary to improve patient selection and to develop novel treatment strategies. Here, we focused on finding mechanisms of acquired resistance to T-DM1 in a panel of HER2 positive breast cancer cell lines (HCC1954, HCC1419 and SKBR3 parental vs. resistant cells) generated by an established protocol of T-DM1 exposure, increasing the concentration of T-DM1[1-4ÎŒg/mL], 3days on/3days off, for 54 days overall. We generated acquired resistant cells with different level of resistance to T-DM1 evaluated by 3, 7 and 10 days proliferation assay, using automated cell counting in SKBR3, HCC1419 and HCC1954 parental and the acquired resistant cells. Analysis of T-DM1 effects on cell cycle showed a significant induction of G2/M arrest in the parental cells, while this effect was not observed in the resistant cells. Expression/activity analysis of cyclin B1/CDK1 complex, the main apparatus involve in G2/M cell cycle arrest induction, showed a remarkable decrease in the basal level of cyclin B1 in the resistant cells. Cyclin B1 accumulation induced by T-DM1 in the parental cells was not observed in the resistant cells. CDK1 activity assay was also correlated with cyclin B1 expression, increasing following T-DM1 treatment in the parental cells, but not in the resistant cells. Functional analysis revealed that cyclin B1 knock down in the parental cells induced a significant T-DM1 resistance. Furthermore, the silencing of cdc20, a protein mainly involved in APC complex related cyclin B1 degradation, could sensitize the resistant cells to T-DM1. Finally, cyclin B1 induction by T-DM1 was confirmed in in vivo and ex vivo xenograft animal model and patients' explants, respectively. By cyclin B1 induction pattern, we could categorize T-DM1 responsive/non-responsive in fresh breast cancer explants from HER2 positive breast cancer patients. Our results showed that T-DM1 induced G2/M cell cycle arrest in a cyclin B1/CDK1 dependent-manner. Lack of these effects appeared in acquired T-DM1 resistant cells. Besides, similar pattern in G2/M and cyclin B1 was verified in vivo and in patients explants. These data strongly suggest that induction of cyclin B1 is necessary for T-DM1 antitumor effects and emerges as a potential pharmacodynamic marker. Our finding also raises the question on what are the mechanisms leading to cyclin B1 dysregulation in resistant cells." -- TDX.

Targeted Therapies In Breast Cancer Book PDF
✏Book Title : Targeted Therapies in Breast Cancer
✏Author : Harold J. Burstein
✏Publisher : Oxford University Press, USA
✏Release Date : 2011
✏Pages : 54
✏ISBN : 9780199735679
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Targeted Therapies in Breast Cancer Book Summary : The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting the ER specifically in breast cancer cells), and letrozole (Femara, targeting the aromatose pathway), raloxifene (Evista, a selective estrogen receptor modulator), ixabepilone (Ixempra, a ?-tubulin inhibitor) have also been approved for various stages and specific settings in breast cancer treatment. The current challenges in the field include further targeting of these agents as part of specific strategies for each patient (biomarker testing, pharmacogenetics, etc.), as well as follow-up and management of adverse events. Part of the Oxford American Pocket Notes series, this volume provides clinicians with the ultra-concise, evidence-based, current information and insight on implementing the latest treatment strategies, including targeted agents, into clinical practice. This portable volume is intended to provide quick, easily accessible guidance for the practicing oncologist, oncology care staff (including nurses and PAs) as well as the primary care practitioner, on the mechanism of action, dosing and administration and adverse effects of the approved targeted agents.

Noninterventional Study Helena Advanced Metastatic Or Locally Recurrent Inoperable Her2 Positive Breast Cancer Book PDF
✏Book Title : Noninterventional Study HELENA advanced metastatic Or Locally Recurrent Inoperable HER2 positive Breast Cancer
✏Author : Marc Thill
✏Publisher :
✏Release Date : 2015
✏Pages :
✏ISBN : OCLC:908831857
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Noninterventional Study HELENA advanced metastatic Or Locally Recurrent Inoperable HER2 positive Breast Cancer Book Summary :

Early Stage Breast Cancer New Developments And Controversies An Issue Of Surgical Oncology Clinics E Book Book PDF
✏Book Title : Early Stage Breast Cancer New Developments and Controversies An Issue of Surgical Oncology Clinics E Book
✏Author : Eleftherios P. Mamounas
✏Publisher : Elsevier Health Sciences
✏Release Date : 2010-07-30
✏Pages : 246
✏ISBN : 9781455700707
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Early Stage Breast Cancer New Developments and Controversies An Issue of Surgical Oncology Clinics E Book Book Summary : This issue of the Surgical Oncology Clinics will focus on new advances in Breast Cancer Surgery, and will include articles on Chemoprevention, Breast MRI, Genomics, Sentinel Node Biopsy, Extra-axillary Sentinel Nodes, Skin-Sparing and Nipple Sparing Mastectomy, Oncoplastic Techniques, Neoadjuvant Hormonal Therapy, Neoadjuvant Chemotherapy, Adjuvant Hormonal Therapy, Adjuvant Chemotherapy, and Biologic Targeted Therapies.

A Step Towards A Her2 Positive Breast Cancer Super Family Book PDF
✏Book Title : A Step Towards a HER2 positive Breast Cancer Super Family
✏Author :
✏Publisher :
✏Release Date : 2015
✏Pages :
✏ISBN : OCLC:1052033757
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏A Step Towards a HER2 positive Breast Cancer Super Family Book Summary :

Cancer Chemotherapy And Biotherapy Book PDF
✏Book Title : Cancer Chemotherapy and Biotherapy
✏Author : Bruce A. Chabner
✏Publisher : Lippincott Williams & Wilkins
✏Release Date : 2011-12-07
✏Pages : 848
✏ISBN : 9781451148206
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Cancer Chemotherapy and Biotherapy Book Summary : Updated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank.

The Key Facts On Breast Cancer Book PDF
✏Book Title : The Key Facts on Breast Cancer
✏Author : Patrick W. Nee
✏Publisher : Patrick W. Nee
✏Release Date : 2013-04-26
✏Pages : 42
✏ISBN : 9781484825129
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏The Key Facts on Breast Cancer Book Summary : The Key Facts on Breast Cancer provides readers with essential, easy-to-read information on the life-threatening disease. Compiled in a simplified manner, this guide helps patients navigate this painful process without enduring the complicated nature of medical terminology. By making a patient-friendly manual to the causes, treatment, and ongoing research of breast cancer, one can easily determine what they are facing and how to live their life to the fullest.

Breast Cancer An Issue Of Surgical Oncology Clinics Of North America  Book PDF
✏Book Title : Breast Cancer An Issue of Surgical Oncology Clinics of North America
✏Author : Lisa Newman
✏Publisher : Elsevier Health Sciences
✏Release Date : 2014-09-08
✏Pages : 241
✏ISBN : 9780323311922
✏Available Language : English, Spanish, And French

Click Here To Get Book

✏Breast Cancer An Issue of Surgical Oncology Clinics of North America Book Summary : This issue of Surgical Oncology Clinics of North America is devoted to "Breast Cancer" and is edited by Lisa Newman, MD, of the University of Michigan. Expert authors in this issue review this topic in articles such as: Applications for Breast MRI; Lobular Neoplasia; Epidemiology of Breast Cancer; Percutaneous Ablation of Breast Tumors; Triple Negative Breast Cancer and the Basal Breast Cancer Subtype; Molecular Profiling of Breast Cancer; Surgical Leadership and Standardization of Multidisciplinary Breast Cancer Care; Neoadjuvant/Primary Systemic Therapy for Breast Cancer; Management of the Clinically Node-Negative Axilla in Patients with Primary and Locally-Recurrent Breast Cancer; Management of the Axilla in Patients with Node-Positive Breast Cancer; Prophylactic Bilateral Mastectomy and Contralateral Prophylactic Mastectomy; Advances in Reconstruction of Mastectomy and Lumpectomy Defects; Nipple-Sparing Mastectomy; and Breast Cancer Disparities.